Reaction Details |
 | Report a problem with these data |
Target | HIV-1 Protease Mutant (I50V) |
---|
Ligand | BDBM8125 |
---|
Substrate/Competitor | HIV Peptide Substrate |
---|
Meas. Tech. | Protease Inhibition Assay |
---|
pH | 5.6±n/a |
---|
Temperature | 310.15±n/a K |
---|
Ki | 2.0±0.4 nM |
---|
Km | 57000±12000 nM |
---|
Comments | Kcat/Km=30±7 min-1nM-1 |
---|
Citation | Kovalevsky, AY; Tie, Y; Liu, F; Boross, PI; Wang, YF; Leshchenko, S; Ghosh, AK; Harrison, RW; Weber, IT Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem49:1379-87 (2006) [PubMed] Article |
---|
More Info.: | Get all data from this article, Inhibition_Run data, Solution Info, Assay Method |
---|
|
HIV-1 Protease Mutant (I50V) |
---|
Name: | HIV-1 Protease Mutant (I50V) |
Synonyms: | n/a |
Type: | Protein Complex |
Mol. Mass.: | n/a |
Description: | n/a |
Components: | This complex has 2 components. |
Component 1 |
Name: | HIV-1 Protease Mutant (I50V) chain A |
Synonyms: | HIV-1 Protease Mutant (I50V) chain B |
Type: | Enzyme Subunit |
Mol. Mass.: | 10718.08 |
Organism: | Human immunodeficiency virus type 1 |
Description: | All of the mutant constructs in this study are on the wild type containing the substitutions Q7K, L33I, and L63I, to minimize the autoproteolysis of the protease, and C67A and C95A, to prevent cysteine-thiol oxidation. |
Residue: | 99 |
Sequence: | PQITLWKRPLVTIKIGGQLKEALLDTGADDTVIEEMSLPGRWKPKMIGGVGGFIKVRQYD
QIIIEIAGHKAIGTVLVGPTPVNIIGRNLLTQIGATLNF
|
|
|
Component 2 |
Name: | HIV-1 Protease Mutant (I50V) chain A |
Synonyms: | HIV-1 Protease Mutant (I50V) chain B |
Type: | Enzyme Subunit |
Mol. Mass.: | 10718.08 |
Organism: | Human immunodeficiency virus type 1 |
Description: | All of the mutant constructs in this study are on the wild type containing the substitutions Q7K, L33I, and L63I, to minimize the autoproteolysis of the protease, and C67A and C95A, to prevent cysteine-thiol oxidation. |
Residue: | 99 |
Sequence: | PQITLWKRPLVTIKIGGQLKEALLDTGADDTVIEEMSLPGRWKPKMIGGVGGFIKVRQYD
QIIIEIAGHKAIGTVLVGPTPVNIIGRNLLTQIGATLNF
|
|
|
BDBM8125 |
---|
Name | BDBM8125 |
Synonyms: | (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-[(2S,3R)-4-[(4-aminobenzene)(2-methylpropyl)sulfonamido]-3-hydroxy-1-phenylbutan-2-yl]carbamate | CHEMBL1323 | Darunavir | Darunavir (DRV) | TMC-114 | UIC-94017 | US10806794, Compound Darunavir |
Type | Small organic molecule |
Emp. Form. | C27H37N3O7S |
Mol. Mass. | 547.664 |
SMILES | [H][C@@]1(CO[C@@]2([H])OCC[C@@]12[H])OC(=O)N[C@@H](Cc1ccccc1)[C@H](O)CN(CC(C)C)S(=O)(=O)c1ccc(N)cc1 |r| |
Structure |  |
HIV Peptide Substrate |
---|
Name: | HIV Peptide Substrate |
Synonyms: | n/a |
Type: | Peptide |
Mol. Mass.: | 3156.95 |
Organism: | n/a |
Description: | n/a |
Residue: | 27 |
Sequence: | Ac-RE(Edans)SQNY*PIVRK(Dabcyl)R-CO-NH2
|
|
|